NANG KUANG
南光化學製藥股份有限公司
NANG KUANG is a Taiwan TWSE-listed biotechnology company; its most advanced asset is ND-340 (Phase 1 completed; Phase 2 application under review, Local anesthesia), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ND-340 | — | Phase 1 completed; Phase 2 application under review | Local anesthesia | — | — | Company disclosure |
| ND-482 | — | — | — | — | 2026-03-31 | Company disclosure |
| ND-483 | — | — | — | — | 2026-03-31 | Company disclosure |
Key events
No verified events in the past twelve months.
Related Drugnews articles
No related articles in this language.